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ABSTRACT 
The transfection of human NTera2/D1 teratocarcinoma-derived cell line (or NT2 cells) 
represents a promising strategy for the delivery of exogenous proteins or biological 
agents into the central nervous system (CNS). The development of suitable non-viral 
vectors with high transfection efficiencies requires a profound knowledge of the whole 
transfection process. In this work, we elaborated and characterized in terms of size and 
zeta potential three different non-viral vectors: lipoplexes (144 nm; -29.13 mV), 
nioplexes (142.5 nm; +35.4 mV) and polyplexes (294.8 nm; +15.1 mV). We compared 
the transfection efficiency, cellular uptake and intracellular trafficking of the three 
vectors in NT2 cells line. Lipoplexes exhibited the highest percentages of EGFP 
positive cells. The values obtained with polyplexes were lower compared to lipoplexes 
but higher than the percentages obtained with nioplexes. Cellular uptake results had a 
clear correlation respect to the corresponding transfection efficiencies. Regarding the 
endocytosis mechanism, lipoplexes enter in the cell, mainly, via clathrin-mediated 
endocytosis (CME) while polyplexes via caveolae-mediated endocytosis (CvME). 
Nioplexes were discarded for this experiment due to their low cellular uptake. By 
simulating an artificial endosome, we demonstrated that the vectors were able to release 
the DNA cargo once inside the late endosome. The data collected from this assay 
showed that at 6h, the genetic material carried by polyplexes was still located in the late 
endosome, while DNA carried by lipoplexes was already in the nucleus. This result 
indicates a faster intracellular traffic of the lipid-based vectors. Overall, our work gives 
new insights into the transfection process of NT2 cells by different non-viral vectors as 
a first step in the development of ex-vivo gene therapy platform.  
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INTRODUCTION 
 
Cell therapy is a field that moves rapidly with new cell lines and tissue-engineered 
constructs developed globally every year. The human NTera2/D1 teratocarcinoma-
derived cell line (or NT2 cells) can be differentiated into well-characterized populations 
of neuron-like cells (or NT2-N) that engraft and mature when are transplanted into the 
adult central nervous system (CNS) of rodents and humans 1-7. Moreover, human 
transplantation studies in the brain of stroke patients demonstrated a lack of 
tumorigenicity of these cells 6, 8. On the other hand, the NT2 cells can be used as cellular 
vehicles with glioma tropism 9, adding a human cell-based delivery vehicle for clinical 
glioblastoma therapy, as it was similarly demonstrated for neural stem cells in animal 
models 10, 11. Although these features suggest that NT2 cells would be an excellent 
platform for ex vivo gene therapy in the CNS 3, 7, 9, 12, 13, the use of non-viral strategies 
for gene transfer has been scarce 14, 15. 
 
In the last decade, cationic lipid-mediated 16 and cationic polymer-mediated non-viral 
gene delivery 17 methods have become useful tools for cellular transfection. Although 
gene therapy is still dominated by viral vectors, which present higher transfection 
efficiencies compared to non-viral gene delivery systems, safety issues such as 
immunogenicity and mutagenicity hinder their clinical applications 18-20. At this point, 
non-viral gene delivery has been the subject of increasing attention due to its relative 
safety, simple use and easy handling compared to viral vectors 21, 22. Among lipid based 
non-viral vectors, liposomes are the most widely used carriers for in vitro and in vivo gene 
delivery 23. Lipofectamine 2000 is a commercialized cationic liposome based reagent, 
which has been extensively used for in vitro gene delivery purposes due to its high 
transfection efficiency 24. In addition to liposomes, niosomes (non-ionic surfactant vesicles) 
have also gained interest as an alternative to liposomes due to their similar structure. 
Although the use of these structures has been mainly restricted to drug delivery, our 
research group has recently obtained some promising results that suggest the possible use of 
cationic niosomes as non-viral vectors for gene delivery 25, 26. Finally, among cationic 
polymers, chitosan is an appropriate candidate for non-viral gene delivery due to its 
biocompatibility, biodegradability and low cost 27. Our research group has been working 
with ultrapure oligochitosan (UOC) obtaining promising results 28, 29. The non-viral carriers 
(liposomes, niosomes or polymers) are typically cationic in nature and electrostatically 
interact with negatively charged DNA molecules forming the so-called lipoplexes, 
nioplexes and polyplexes, respectively.  
 
Regardless the gene carrier, it is well known that the final gene expression will be highly 
influenced by the uptake of the non-viral vector, the internalization pathway and, their 
ability to escape from the endosomes and import the genetic material into the nucleus 30. At 
the same time, the internalization route of the vectors will depend on their composition and 
physicochemical characteristics, such as size, polydispersity, surface charge and 
morphology 31. Thus, it is essential to study, specifically, the uptake and intracellular 
trafficking of each selected non-viral vector, to understand their possible limitations and 
improve their design.  
 
Therefore, this work was intended to carry out a comparative study of three types of non-
viral vectors in human neuronal precursor NT2 cell line. Specifically, we compared 
lipoplexes based on the commercialized Lipofectamine 2000; nioplexes based on a 
previously described novel noisome formulation; and polyplexes based on UOCs. For this 
purpose, the vectors were characterized in terms of size, polydispersity index (PDI) and 
surface charge. The percentage of transfected cells, mean fluorescent intensity (MFI) and 
cell viability were analyzed by flow cytometry. Additionally, the expression of the 
enhanced green fluorescent protein (EGFP) was analyzed by Western Blot. To further 
explain the differences in the transfection efficiencies that among the three formulations, we 
performed qualitative and quantitative cellular uptake studies, by confocal microscopy and 
flow cytometry, respectively, using Cy3 or FITC labeled plasmids. The endocytosis 
pathways of the studied vectors were determined by colocalization assays and quantified by 
the Mander´s overlap coefficient. Finally, the endosomal escape was analyzed by 
simulating the interaction of the vectors with anionic micelles, analogues of endosomal 
compartment.  
 
MATERIAL AND METHODS 
 
Propagation of pCMS-EGFP 
The pCMS-EGFP reporter plasmid was purchased from Plasmid Factory (Bielefeld 
Germany) and was propagated in Escherichia coli DH5-α and purified using the Qiagen 
endotoxin-free plasmid purification Maxi prep kit (Qiagen, Santa Clarita, CA, USA) 
according to the manufacturer’s instructions. The concentration of pDNA was 
quantified by measuring the absorbance at 260 nm using a NanoDrop® (ND-1000 
spectrophotometer, Thermo Fisher Scientific Inc., Denver, USA). The purity of the 
plasmid was verified by agarose gel electrophoresis in Tris-borate-EDTA buffer, pH 8.0 
(TBE buffer). DNA bands were detected using GelRed™ (Biotium, Hayward, 
California, USA) and images were observed with a ChemiDoc™ MP imaging system 
(Bio-Rad, USA). 
 
Niosomes elaboration 
The cationic lipid 2,3-di(tetradecyloxy)propan-1-amine used for niosome elaboration 
was synthesized as previously described by Grijalvo et al. 32. Niosomes were prepared 
by the oil in water (o/w) emulsification method 26. 5 mg of the cationic lipid were gently 
ground with 20 µl of squalene. Then, 1 ml of dichloromethane was added and 
emulsified with 5 ml of an aqueous phase containing the non-ionic surfactant 
polysorbate 80 (0.5 %, w/w). The emulsion was obtained by sonication (Branson 
Sonifier 250, Danbury) for 30 s at 50 W. The organic solvent was removed from the 
emulsion by evaporation under magnetic agitation for three h. Upon dichloromethane 
evaporation, a dispersion containing the nanoparticles was formed by precipitation of 
the cationic nanoparticles in the aqueous medium. The final concentration of the 
cationic lipid in the niosome formulation was 1mg/ml. 
 
Preparation and characterization of the complexes 
Lipoplexes, nioplexes, and polyplexes were prepared by mixing at determinate 
weight/weight (w/w) ratios Lipofectamine 2000 (Invitrogen, Life Technologies, USA) 
solution, niosomes or UOC (Novafect O15 with a molecular weight of 5.7 KDa and 97 
% degree of deacetylation, purchased from NovaMatrix/FMC, Sandvika, Norway) 
solution with the pCMS-EGFP plasmid. (i) Lipoplexes were prepared at a 
Lipofectamine/DNA w/w ratio of 2:1 by mixing gently Lipofectamine solution 
(1mg/ml) and pCMS-EGFP solution (0.5 mg/ml) (ii) Nioplexes were prepared at a fixed 
cationic lipid/DNA ratio 20:1 (w/w). (iii) For polyplexes preparation, UOC solution was 
dissolved in miliQ water to a final concentration of 2 mg/ml. pCMS-EGFP solution was 
added under vortex mixing (15 s) to the chitosan solution at a final UOC/DNA w/w 
ratio of 13:1. In all cases, the formulations were incubated for 30 minutes at room 
temperature to allow the correct formation of the complexes.  
 
The complexes were characterized in terms of size and zeta potential. The 
measurements were carried out as previously described by Ojeda et al. using a Zetasizer 
NanoZS (Malvern Instruments, UK) 26. Briefly, 50 µl of the complexes containing 
0.625 µg pCMS-EGFP were resuspended in 950 µl of NaCl 0.1 mM. The particle size 
reported as hydrodynamic diameter was obtained by Dynamic Light Scattering, and the 
zeta potential was obtained by Laser Doppler Velocimetry. All measurements were 
carried out in triplicate.  
 
Cell culture and transfection protocol 
Human teratocarcinoma NTERA2/D1 (NT2) cells from the American Type Culture 
Collection (ATCC®, CRL-1973™) were maintained in complete medium: Dulbecco’s 
Modified Eagle medium (DMEM®, ATCC 30-2002™), supplemented with 10% fetal 
bovine serum (FBS, Sigma-Aldrich, St Louis, MO, USA ) and antibiotics (100 U/mL 
penicillin and 100 µg/mL streptomycin, Gibco, Life Technologies S.A., Madrid, Spain), 
at 37ºC under a humidified atmosphere containing 5% CO2. 
Before transfection, NT2 cells were seeded in 24 well plates at an initial density of 8 × 
104 cells per well with 400 µl complete medium and allowed to grow to 70-80 % 
confluence. Then, the complete medium was replaced with serum-free Opti-MEM® 
(Gibco, Life Technologies S.A.), and the cells were exposed to the complexes at the 
corresponding w/w ratios (containing 1.25 µg pCMS-EGFP per well) (Table 1). In the 
case of polyplexes, Opti-MEM® containing 270 mM mannitol was used to obtain a final 
isotonic medium. Also, the pH was adjusted to 7 with HCl 0.1N, as it has been 
previously described the improved transfection with this kind of formulations at slightly 
acidic pH values. After four hours of incubation at 37 ºC, the complexes were removed 
and replaced with 380 µl complete medium and were allowed to grow until the analysis 
time.  
 
 
  
 
Formulation Main component 
w/w 
ratio 
DNA 
quantity (µg) 
Lipoplexes Lipofectamine 2000 reagent 2:1 1.25 
Nioplexes 
2,3-di(tetradecyloxy)propan-1-amine 
cationic lipid 
20:1 1.25 
Polyplexes Novafect O15 ultrapure oligochitosan 13:1 1.25 
 
Table 1: Summary of the main components, w/w ratios and DNA quantities employed for the 
elaboration of the three formulations.  
 
Analysis of EGFP expression and cell viability  
Qualitative expression of EGFP was analyzed using an inverted microscope equipped 
with an attachment for fluorescent observation (model EclipseTE2000-S, Nikon). Flow 
cytometry analysis was conducted using a FACSCalibur system flow cytometer (Becton 
Dickinson Biosciences, San Jose, USA), in order to quantify the percentage of EGFP 
positive cells and the mean fluorescent intensity (MFI). At the end of the incubation 
period, cells were detached with 200 µl of trypsin/EDTA and, 400 µl of complete 
medium were added to inhibit trypsin activity. Then, cells were transferred to specific 
flow cytometer tubes to quantify EGFP expression. For cell viability measurements, 5 
µl of the BD-via probe reagent (7-AAD) was added to each sample. Transfection 
efficiency was expressed as the percentage of EGFP positive cells at 525 nm (FL1), and 
cell viability was expressed as the percentage of 7-AAD negative cells at 650 nm (FL3). 
Control samples (non-transfected cells) were displayed on a dot plot of forward scatter 
against side scatter to establish a collection gate. For each sample, 10,000 events were 
collected. 
 
In addition, EGFP protein expression was analyzed by Western Blot of whole cell 
homogenates. Thus, expression was analyzed semiquantitatively at 24, 48 and 72 h after 
transfection with the different reagents. For each independent analysis, cells from 3 
wells per condition were lysed and pooled in 300 µl lysis buffer: Tris-HCl (50 mM, pH 
7.4), 150 mM NaCl, 1% Igepal (Sigma-Aldrich), 0.5% sodium deoxycholate (Sigma-
Aldrich), 0.1% sodium dodecyl sulfate (SDS), 2.5 mM CHAPS (Sigma-Aldrich) and 
protease inhibitor cocktail (50 µl/mg protein; Sigma-Aldrich). Solubilized proteins were 
collected from supernatants of samples after centrifugation at 40,000 x g for 5 min at 4 
ºC). Protein concentrations were determined with the BCA protein quantification kit 
(Abcam, Cambridge, UK; BD Transduction Laboratories, San Diego CA, USA). 
Increasing amounts (4, 6, 8, 10 µg) of proteins from cells 24 h after transfection with 
Lipofectamine 2000 and 10 µg of samples from the rest of conditions were run in 
parallel and resolved by electrophoresis on SDS-polyacrylamide (SDS–PAGE) 10% 
gels. The uppermost part of the gel containing proteins above the 75 kDa standard was 
separated and stained with Coomassie Blue for a protein load control. The rest of 
proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Amersham 
Bioscience, Buckinghamshire, UK). Blots were blocked in 5% non-fat dry 
milk/phosphate buffered saline containing 0.5% BSA and 0.2% Tween (blocking 
buffer) for 1 h, and incubated with rabbit polyclonal anti-GFP antibody (Invitrogen, 
Ref. A11122) 1:2000 diluted in blocking buffer. After extensive washing, the PVDF 
membranes were incubated with horseradish peroxidase-conjugated secondary 
antibodies diluted to 1:10,000 in blocking buffer for 2 h at room temperature. 
Immunoreactive bands were detected with ECL reagent according to the manufacturer’s 
instructions (Amersham Bioscience, Buckinghamshire, UK). EGFP-specific 
immunoreactive bands were acquired from four independent experiments using an 
ImageQuant 350 imager (GE Healthcare, Madrid, Spain) and quantified by 
densitometry using ImageJ image analysis software (ImageJ, NIH, Bethesda, MD, 
USA). Optical density (OD) values from bands corresponding to increasing protein 
amounts from Lipofectamine 2000-transfected at 24 h post-transfection were used for 
linear regression analysis. Thus, we obtained a linear regression equation, which 
allowed us to calculate the fold change of EGFP immunoreactivity for each condition 
(transfection reagent and post-transfection time) compared to the samples from cells at 
24 h after transfection with Lipofectamine 2000. 
 
Cellular uptake assays 
NT2 cells were cultured and seeded as for transfection experiments. Then, the regular 
growth media was removed from the wells and the cells were exposed to the complexes 
containing 1.25 µg of the pCMS-EGFP labelled with fluorescein isothiocyanate (FITC) 
(DareBio, Spain) or Cy3 (Mirus Bio Corporation, Madison, WI). After 1h or 4h of at 37 
ºC, the transfection medium was removed and cells were washed with PBS and fixed 
with formaldehyde 4% for the quantitative and qualitative analysis, by flow cytometry 
and confocal laser scanning microscopy (CLSM), respectively. Each formulation was 
analyzed by triplicate. 
 
Cells were analyzed after 1 h or 4 h of incubation by flow cytometry at 525 nm (FL1) 
after detachment from the wells. 10,000 events were collected for each sample. Cellular 
uptake data was expressed as the % of FITC positive cells. For the qualitative study, 
cells were seeded on coverslips containing plates and treated with the vectors 
(containing Cy3 labelled DNA). After 4h of incubation, cells were stained with 
Phalloidin AlexaFluor-488 and preparations were mounted on Dapi Fluoromount-G 
(Southern Biotech) and then, images were obtained with an Olympus Fluoview FV500 
microscope. CLSM images were captured in the General Service of Analytical 
Microscopy and High Resolution in Biomedicine of the University of the Basque 
Country (UPV/EHU, Bizkaia, Spain). 
 
Colocalization assays 
The endocytic processes involved in the internalization of the complexes were analyzed 
by colocalization assays. NT2 cells were seeded on coverslips (as described for 
transfection protocol) and co-incubated with the complexes (containing the FITC 
labeled pCMS-EGFP) and different endocytosis fluorescent markers: AlexaFluor546-
Transferrin (50 µg/ml), AlexaFluor555-Cholera toxin (10 µg/ml) or Lysotracker (140 
nM), which are markers for clathrin-mediated endocytosis (CME), caveolae/raft-
mediated endocytosis (CvME) and late endosomal compartment, respectively. After 3 
hours of incubation with the complexes, the markers were added to the cells, and they 
were incubated one more hour. Then, the cells were fixed with formaldehyde 4% and 
mounted on DAPI fluoromont G for their posterior examination by CLSM. 
Colocalization of the green and red signal was analyzed by ImageJ software and 
quantified by the Mander´s coefficient 33.  
 
Vulnerability assay of the complexes in the late endosome 
As an analogue of the endosomal compartment, anionic micelles based on 
phosphatidylserine (PS) (Sigma-Aldrich, Spain) were prepared, as described previously 
34
. PS was dissolved in chloroform at 1.6 mM and left under magnetic stirring until the 
solvent was completely evaporated. Phosphate buffer was added to the dried sample, 
and a dispersed solution was obtained by sonication (Branson Sonifier 250, Danbury). 
PS micelles and the complexes were incubated at a w/w ratio of 1:50 (pCMS-EGFP: 
PS) for1 hour. After that, the amount of the released DNA from each complex was 
determined by agarose gel electrophoresis. Naked plasmid or complexes (containing 
205 ng pCMS-EGFP) were loaded onto a 0.8 % agarose gel and exposed for 30 min to 
100 V. DNA bands were stained with GelRed™ (Biotium, Hayward, California, USA) 
and images were observed with a ChemiDocTM MP Imaging System (BioRad, Madrid, 
Spain) and analyzed with Image LabTM software (Bio-Rad, Madrid, Spain). 
 
Statistical analysis 
 
All data are expressed as mean ± SD, n=3. The Kruskal-Wallis Test and Dunn’s 
Multiple Comparison post-test were applied with InStat programme (GraphPad 
Software, San Diego, CA, USA) to make statistical comparisons. Differences were 
considered statistically significant when P<0.05. 
 
RESULTS  
 
Size, PDI and zeta potential of the complexes 
Fig. 1 summarizes the characterization of the complexes. While lipoplexes and 
nioplexes presented a particle size around 140 nm with low PDI (0.21), polyplexes 
showed bigger size (294 nm) and PDI (0.44) (Fig. 1A). The higher polydispersity of the 
polyplexes can also be observed in the size distribution curve (Fig. 1B). Regarding the 
surface charge, it varied from negative to positive values depending on the vector. 
Lipoplexes were negatively charged (-29.13 mV) while nioplexes and polyplexes had a 
positive zeta potential, +35.4 mV and +15.1 mV, respectively (Fig. 1A). 
 Figure 1. Characterization of the complexes. (A) Size, PDI, and zeta potential values. Each value 
represents the mean ± standard deviation of three measurements. (B) Size distribution curve of the 
complexes. 
 
NT2 cell viability and EGFP expression 
The percentage of viability was determined by flow cytometry at 24, 48 and 72 h post-
incubation. Cell viability was above 70 % in the three tested formulations at all 
analyzed times (Fig. 2), showing minimal differences among the formulations in all 
tested times.  
 
 
 
Figure 2. Cell viability of NT2 cells at 24, 48 and 72 hours after the treatment with the complexes. Error 
bars represent ± SD (n=3). *P < 0.05 
 
The percentage of EGFP positive live cells at 24, 48 and 72 hours post-transfection was 
analyzed by flow cytometry (Fig. 3A). No statistical differences were observed among 
the tested times except for lipoplexes; in this case, a significant decrease was observed 
at 72h (37 %) compared to 24 h (22 %). Among the three formulations, lipoplexes 
exhibited the highest transfection percentages (up to 35 % at 24 h), and nioplexes the 
lowest (5 %), while polyplexes were able to transfect almost 20 % of the cells. 
Microscopic photographs (Fig. 3B) corroborated these results, as almost no EGFP 
positive cells were observed after their transfection with nioplexes (Fig. 3 B6). A well-
defined cell population can be found in flow cytometry dot plots (FSC vs. SSC) in all 
cases (Fig. 3 C1, C3, C5, and C7). In FL1 (GFP) vs. FL3 (7-AAD) dots plots, the higher 
transfection efficiency of lipoplexes (Fig.3 C4) and polyplexes (Fig. 3 C8) compared to 
nioplexes (Fig. 3 C6) and the non-treated cells (Fig. 3 C2) is explicitly represented. 
 
Figure 3. Transfection efficiency of the three tested complexes. (A) Bar graphs showing the percentage 
of EGFP positive live cells at 24, 48 and 72 hours post-transfection. Error bars represent ± SD (n=3) *P < 
0.05. (B) Microscope photographs of NT2 cells at 48 h post-transfection. (B1, B4, B7) phase contrast 
images, (B2, B5, B8) fluorescent images and, (B3, B6, B9) overlay images of cells transfected with (B1, 
B2, B3) lipoplexes, (B4, B5, B6) nioplexes and (B7, B8, B9) polyplexes. (C) Flow cytometry dot plots 
representing (C1, C2, C3, C5, C7) FSC vs SSC and (C2, C3, C4, C6, C8) FL1 vs FL3 of NT2 cells treated 
with (C1, C2) negative control, (C3, C4) lipoplexes, (C5, C6) nioplexes and (C7, C8) polyplexes, 48 
hours post transfection. FL1 channel corresponds to GFP and FL3 channel corresponds to 7-AAD. 
 
In order to show the production of EGFP in the cells, MFI of the transfected cells was 
calculated (Fig. 4A) and Western Blot analysis of EGFP expression was performed 
(Fig. 4B). Both, MFI measurements and densitometric analysis of EGFP 
immunostaining revealed that lipoplexes and nioplexes exhibited the highest and the 
lowest MFI values, respectively. Interestingly, lipoplexes showed the highest MFI 
values, while nioplexes the lowest. Kruskal-Wallis test followed by Dunn’s multiple 
comparisons revealed no statistical differences in MFI among the tested times except for 
polyplexes. In this case, a significant increase is observed at 48 hours compared to the 
previously studied time. In contrast, significant differences were found between the 
different formulations. Specifically, 24 and 48 hours after transfection, MFI values were 
significantly higher in lipoplexe- than in nioplexe-transfected cells and significant 
differences were also detected at 72 hours between nioplexe- and polyplexe-transfected 
cells (Fig. 4. A). In addition, Western blot analysis corroborated these results. As seen 
in Fig. 4B, barely detectable EGFP was produced after transfection with nioplexes. By 
contrast, a well-defined band appeared with lipoplexes and polyplexes, at all tested 
points. In agreement with MFI values, a more intense EGFP band was obtained with 
lipoplexes. 
 
 
 
 
Figure 4. Expression of EGFP protein at 24, 
48 and 72 hours post-transfection. (A)  A bar 
graph showing MFI values for cells 
transfected with the different complexes. Error 
bars represent mean ± SD (n=3). (B) Bar 
graph depicts results of the semiquantitative 
analysis of EGFP protein expression by 
Western Blot. A representative Western Blot 
is shown below the bar graph. Error bars 
represent mean ± SD (n=4). Kruskal-Wallis 
test followed by Dunn’s multiple comparison 
post-test. *P < 0.05, **P < 0.01. 
 
 
 
Cellular uptake 
The flow cytometry analysis carried out with FITC-labelled pDNA complexes indicated 
that cellular uptake was clearly time dependent. The percentage of FITC positive cells 
increased along the time, from 50 % (lipoplexes), almost no uptake (nioplexes) and 20 
% (polyplexes) after 1 h of incubation, to 70 % (lipoplexes), 10 % (nioplexes) and 30 % 
(polyplexes) after 4 h of incubation with the complexes (Fig. 5A). However, statistical 
differences were only observed between lipoplexes and nioplexes. In the flow cytometry 
histogram (Fig. 5B) the uptake of the complexes after four hours of incubation is 
observed: lipoplexes > polyplexes > nioplexes. Confocal microscope images supported 
the quantitative results (Fig. 5 C1, C2, and C3).  
 
 
Figure 5. Cellular uptake of the complexes. (A) Bar graphs showing the percentage of FITC positive NT2 
cells after the incubation for 1 hour or 4 hours with the complexes. Error bars represent ± SD (n=3). *P < 
0.05. (B) Flow cytometry histograms representing the cellular uptake of the complexes (formed with 
FITC labelled plasmid DNA) after 4 h of incubation. Black filled curve represents untreated cells. (C) 
Merged images of NT2 cells four hours after the addition of (C1) lipoplexes, (C2) nipolexes and (C3) 
polyplexes. Images are at 63X magnification. Blue colouring shows cell nuclei stained with DAPI; red 
colouring shows F-actin stained with Phalloidin; green colouring shows Cy3 labelled plasmid DNA 
complexed with the corresponding non-viral vector. 
 
Cell uptake mechanisms 
The presence of CME and CvME pathways in NT2 cells was determined with specific 
markers of endocytic routes, Transferrin-Alexa Fluor and Cholera Toxin-Alexa Fluor, 
respectively. Flow cytometry histograms (Fig. 6 A1 and A2) illustrated that almost 100 
% of NT2 cells were appropriately stained after the treatment with fluorescent markers. 
This data indicated that both CME and CvME are present in the studied cell line.  
 
Fig. 6B illustrates the confocal images four hours after the co-treatment with the 
endocytosis markers (red) and lipoplexes /polyplexes (green). Due to the low cellular 
uptake of nioplexes, this formulation was discarded for uptake mechanism studies. 
Colocalization of red and green fluorescence showed visible yellow/orange punctate 
structures (Fig. 6B). In addition, we performed a quantitative analysis; the 
colocalization values were represented as the fraction of complexes colocalized with the 
fluorescently labelled endocytic structures, represented by the Mander´s (M1) 
coefficient. The colocalization value of lipoplexes with Transferrin-Alexa Fluor (marker 
of CME pathway) was higher than the colocalization with Cholera toxin-AlexaFluor 
(marker of CvME pathway): Mander´s overlap coefficients were 0.471 and 0.367, 
respectively (Fig.6 B1 and B2). The overlap coefficients were superior for polyplexes, 
0.576 with CME marker and 0.697 with CvME marker (Fig.6 B3 and B4).  
 Figure 6. Endocytosis pathway of the complexes. (A) Flow cytometry histograms of cells treated with 
(A1) Transferrin-Alexa Fluor 488 at 50 µg/ml and (A2) Cholera toxin-Alexa Fluor 488 at 10 µg/ml. 
Black filled curve represents untreated cells. (B) Colocalization of test complexes (formed with FITC 
labelled plasmid DNA) (green) with the specific markers of endocytic pathways (red): clathrin-mediated 
endocytosis (Alexa Fluor 546-Transferrin at 50 µg/ml) and caveolae-mediated endocytosis (Alexa Fluor 
555-cholera toxin at 10 µg/ml). The images were taken after 4 hours of incubation with the test 
complexes. Images are at 63x magnification. Nuclei are stained with DAPI (blue). The presence of yellow 
colour represents the overlay of the endocytic pathway marker and the vectors. The colocalization values 
are given as the fraction of complexes colocalizing with fluorescently labelled endocytic structure, 
represented by Mander´s (M1) coefficient.   
 
Intracellular trafficking and endosomal escape 
The colocalization of the complexes with the late endosomes at 4 and 6 hours was 
visualized and quantified by labelling the endosomal compartment with a specific 
marker: Lysotracker (red colour). Colocalization of red and green fluorescence gave rise 
to visible yellow/orange punctate structures (Fig. 7A). The quantitative value was given 
as the Mander´s overlap coefficient. The results showed that polyplexes were located 
mainly in the late endosome after 4 hours (M= 0.735), and remained at least until 6 h 
(M=0.764). The values with lipoplexes were lower at both times (0.543 at 4h and 0.489 
at 6h). In Fig. 7 A we observed that at 6 hours, the DNA carried by lipoplexes was 
located in the nucleus, and even at 4 hours this was evident. 
 
In order to evaluate whether the complexed DNA can be released from the endosomes, 
we examined the amount of released DNA after mixing the complexes with the 
previously elaborated PS micelles. The vesicles showed sizes of 170 nm and zeta 
potential of -65 mV. As observed in the agarose gel (Fig. 7C), DNA was released from 
all the complexes after their incubation with PS micelles (Fig. 7B). Almost 80 % of the 
total DNA was released from lipoplexes (lane 2); 40 % from nioplexes (lane 3) and 30 
% from polyplexes (4). The release of the DNA was lower without the previous 
incubation with the anionic micelles: 30 %, 5% and 0 % with lipoplexes (lane 5), 
nioplexes (lane 6) and polyplexes (lane 7), respectively. 
 
 
Figure 7. (A) Colocalization of test complexes (formed with FITC labelled plasmid DNA) (green) with 
Lysotracker Red-DND-99 that is a specific marker of the late endosome (red). The images were taken 
after 4 and 6 hours of incubation with the test complexes. Markers were added 1 hour prior to the end of 
the incubation time. Images are at 63 x magnification. Nuclei are stained with DAPI (blue). Presence of 
yellow colour represents the overlay of the endocytic pathway marker and the vectors. The colocalization 
values are given as the fraction of complexes colocalizing with fluorescently labelled endocytic structure, 
represented by Mander´s (M1) coefficient. (B) DNA release profiles measured with gel electrophoresis. 
Lane 1: naked DNA; lane 2: lipoplexes incubated with PS; lane 3: nioplexes incubated with PS; lane 4: 
polyplexes incubated with PS; lane 5: lipoplexes; lane 6: nioplexes; lane 7: polyplexes. PS refers to 
phosphatidyl serine micelles. (C) The percentage of released DNA quantified from the agarose gel using 
the Image Lab TM software.  
 
DISCUSSION 
The transfection of the well-established, human NT2 or NT2-N cells is widely 
employed to obtain suitable platforms for the delivery of exogenous proteins into the 
CNS 3, 7, 12, 13. Indeed, the glioma tropism of NT2 cells 9 makes this undifferentiated cell 
line an interesting tool to derive new cellular vehicles for clinical glioblastoma therapy. 
Until now, most of the studies based on genetically engineered NT2 cells rely on the use 
of viral vectors. However, the development of non-viral transfection strategies to 
produce stable or transient population of NT2 cells expressing exogenous gene products 
has distinct advantages, especially if they are subsequently grafted into animals´ models 
of human nervous system diseases. 
 
The successful design of non-viral carriers for gene delivery requires a profound 
understanding of the transfection process, which is a complex multi-step process 
influenced by several factors. The vector is first bound to the cell membrane followed by 
internalization through an endocytic route. To avoid lysosomal degradation, the genetic 
material has to be released from the endosomes into the cytoplasm and target the 
nucleus to start the transcription process and protein synthesis. 30. In recent years, many 
non-viral vectors have been developed, and their efficient transfection has been 
demonstrated. However, less attention has been paid to the transfection process itself, 
starting from the binding to the cell membrane until the DNA reaches the nucleus. 
Regarding the gene delivery to NT2 cells, no works concerning the whole transfection 
process mediated by lipoplexes, nioplexes or polyplexes have been previously reported. 
The understanding of how the physicochemical characteristics of the vectors influence 
their intracellular traffic could lead to the design of new formulations with specific 
characteristics that could favour an appropriate intracellular pathway to obtain high 
transfection efficiencies. Thus, we have compared in neuronal precursor NT2 cells the 
transfection efficiency and uptake mechanisms of three different non-viral vectors.  
 
The physicochemical characteristics and the composition of the non-viral vectors 
influence their interaction with the cell membrane and their intracellular uptake 31, 35. 
Thus, the characterization of the complexes is essential to understand better their 
behavior when they are in contact with the cells. The data obtained from lipoplexes 
based on Lipofectamine (size of 144.1 nm and zeta potential of -29.13 mV) (Fig. 1) is 
corroborated by other works, where lipoplexes elaborated with Lipofectamine (w/w 
ratio 4:1) had similar size and zeta potential values (150 nm and -0.4 mV) 36. The lower 
zeta potential that we obtained could be explained due to the lower w/w (2:1) that we 
used to elaborate the lipoplexes. Concerning nioplexes and polyplexes, our previous 
works supported our current results 25, 28. 
 
The transfection efficiency of the three vectors and the EGFP production was analyzed 
along the time. Our findings revealed that negatively charged lipoplexes exhibited the 
highest transfection efficiencies and protein expression levels 37-39, which decreased along 
the time (Fig. 3 and Fig. 4). Lipofectamine is a well-known transfection agent with high 
transfection efficiency 36. Although we did not show significant toxicity signs in NT2 cell 
line with our in vitro viability assay (Fig. 2), we previously reported the in vitro cytotoxicity 
of Lipofectamine in other cell lines 25.Thus, the in vivo application of this reagent has been 
limited due to its high toxicity compared to other compounds 40. Our group has previously 
reported positive results obtained with nioplexes in vitro, ARPE 19 cells, and in vivo 25. 
Surprisingly, nioplexes did not exhibit the expected transfection efficiencies in NT2 cells. 
So, we must consider that transfection efficiency is cell line dependent 41. As an alternative 
to lipid-based vectors, low molecular weight, and highly deacetylated chitosan have showed 
promising results 28, 29, 42. Against all predictions, our results indicated that polyplexes were 
more efficient for the transfection of NT2 cells than nioplexes. Although the transfection 
efficiency values were lower than the ones obtained with lipoplexes (15 % versus 35 % at 
24 h shown in Fig. 3), the low toxicity of this polymer enhances its possible clinical 
applications. Moreover, we should consider that the transfection efficiency of chitosan 
could be enhanced by its conjugation with several compounds 43. 
 
In order to understand the differences in the transfection efficiency observed between the 
vectors, the cellular uptake of the carriers was determined after 1 and 4 hours of incubation 
(Fig. 5). The time dependent cellular uptake was already described before by Apaolaza et al. 
They reported that the cellular uptake of solid lipid nanoparticles in ARPE19 and HEK293 
increased along the time, obtaining the highest results after 8h of incubation 44. Douglas et 
al. described that the cellular uptake of alginate-chitosan nanoparticles in 293T, COS7 and 
CHO cells reached a plateau by 2 h post-treatment 41. As our transfection experiments were 
stopped after 4 h of incubation, we decided not to prolong the uptake studies more than 4h 
since our aim was only to compare the cellular uptake of the three formulations. The 
cellular uptake was clearly influenced by the carrier type. Lipoplexes (negatively charged) 
entered in almost 70 % of the cells at 4h and polyplexes (positively charged) in 30 % of the 
cells. Although the uptake of positively charged nanoparticles is presumably favored, the 
evidence of uptake of negatively charged nanoparticles has been reported. Despite the 
expected unfavorable interaction between the particles and the negatively charged cell 
membrane 45, recent work by Gainza et al. has reveled high uptake levels of lipid carriers (-
34 mV) in several cell lines 46. The uptake of negatively charged lipoplexes could be 
explained due to the interactions that may exist between the cationic lipids present in 
lipoplexes formulation and the lipid compounds in the cell membrane. Despite the desirable 
physicochemical characteristics observed in the nioplexes, (140 nm and +35 mV), we 
unexpectedly found that the cellular uptake of these vectors in NT2 cells was very low (10 
% at 4h). Mochizuki et al. also reported low cellular uptake results with complexes based on 
cationic lipids and FITC labeled DNA 34. By contrast, our research group has preliminary 
results that indicate that the cellular uptake of these nioplexes is almost 100 % in ARPE19 
cells. All these data suggest that it is necessary to investigate the behavior of the 
formulations in every selected cell lines. Overall, the cellular uptake results showed an 
apparent correlation respect to the corresponding transfection efficiency.  
 
In order to obtain further information about the transfection process of our carriers and 
considering the different physicochemical characteristic of the studied vectors, we 
performed colocalization studies to elucidate if the characteristics of the vectors could 
influence their uptake mechanism and intracellular traffic. Due to the low cellular uptake of 
nioplexes, these were discarded for the following experiments. Endocytosis has been 
postulated as the principal mechanism of entry for non-viral vectors. Regarding 
nanoparticle uptake, CME and CvME are the most common and studied endocytosis routes 
47
. By confocal imaging and colocalization assays (Fig. 6), we concluded that cell entry of 
lipoplexes (140 nm, -29 mV) occurred mainly through CME, while polyplexes (290 nm, 
+15 mV) entered the cell mainly by CvME. However, we did not observe radical 
differences, indicating that both pathways would be involved in the uptake of the two 
formulations. Although the data reported in the literature regarding the relationship between 
nanosizes and endocytic pathways is sometimes inconsistent, according to Rejman et al. 
internalization of microspheres with diameter < 200 nm involved clathrin-coated pits, while 
an increase in size provoked a shift of the mechanism that relies on caveolae-mediated 
endocytosis 48. Moreover, the internalization process may be also affected by the 
components of the vectors. The entry of Lipofectamine based lipoplexes by the CME in a 
myoblast cell line was previously reported by Billiet et al. 36. Peng et al. described that 
chitosan/poly(g-glutamic acid) complexes were internalized by macropynocitosis and 
caveolae-mediated pathway in HT1080 human fibrosarcoma cell line 49. The major problem 
of analyzing the effects of the size in the trafficking process is the high polydispersity of 
many nanomaterials, as it occurs with our chitosan based polyplexes, where large and small 
particles coexist and different entry pathways may be involved. The surface characteristics 
of nanoparticles can also influence their internalization mechanisms. Unlike our results, 
according to the literature, positively charged vectors predominantly internalize through 
CME, while negatively charged formulations utilize CvME 50. Nevertheless, exemptions 
including negatively charted PLGA nanoparticles that enter the cell through caveolae-
independent pathways and PEI based cationic polyplexes that utilize CvME have also been 
reported in the literature 47, 51. In addition, we cannot forget that apart from CME and 
CvME, clathrin- and caveolae- independent endocytosis routes may also take part in the 
internalization of the nanoparticles 35, 52. It is worth mentioning that depending on the cell 
line the internalization pathway of a particular complex could vary. Thus, our results should 
only be considered for the NT2 cell line.  
 
At 4 hours, the highest colocalization for both lipoplexes and polyplexes was observed in 
the late endosome (Fig. 7) being superior with polyplexes, (0.735) compared to lipoplexes 
(0.543). Particles that enter via CME are confined within endosomes that will suffer a 
maturation process involving the compartment acidification that results in late endosomes 
and finally, lysosomes. Although some authors described the CvME as a route away from 
lysosomal degradation, recently, it has been postulated that the caveosomes are considered 
to fuse with normal acidified endosomes, allowing the transfer of material to lysosomes 53. 
This hypothesis supports our results since the polyplexes that enter the cell mainly via 
caveolae-mediated pathways were entrapped in the late-endosomes. In addition, the particle 
transport mechanism (active transport or diffusion) could define the final fate of the 
complexes. Particles that are actively transported are usually shuttled from endosomes to 
lysosomes for degradation 54. Thus, the next step in the transfection process consists in the 
endosomal escape of the DNA to avoid lysosomal degradation. Several endosomal escape 
mechanisms are described in the literature, which vary depending on the nanoparticle 55. A 
widely used approach consists of the “proton-sponge effect” which involves nanoparticles 
having a high buffering capacity, as it is the case of cationic polymers such us PEI. We 
previously described that UOC posse’s higher buffering capacity that high molecular 
weight chitosans 56. Another mechanism involves the electrostatic interactions between the 
nanoparticles and the anionic lipids of the endosome membrane, which causes the 
destabilization of the endosomal membrane allowing the release of the cargo. As an 
analogue of the endosomal compartment, we elaborated anionic micelles made from PS, 
according to Mochizuki´s et al. protocol 34. As observed in Fig. 7B and 7C, the contact of 
the vectors with the PS micelles led to the release of the DNA from the particles. This 
simulated the ability of the studied formulations to release the DNA once they contact the 
lipid membrane of the endosome, which is a requisite for an efficient transfection.  
 
The velocity of the internalization process could vary depending on the carrier, especially 
depending on its size 48. We observed a difference in the internalization velocity of the two 
studied vectors that could be related to the differences in their size. The colocalization 
values that we achieved with lipoplexes and the specific markers at 4 h and 6 h were lower 
compared to the values obtained with polyplexes, which means that at the tested times most 
of the lipoplexes were not located within the endosomes. Moreover, 6 h after the addition of 
the particles to the cells, the FITC-labeled DNA carried by lipoplexes was found in the 
nucleus while the DNA carried by polyplexes was still located within the late endosomes 
(Fig.7A). These findings suggested that the internalization process of lipoplexes is a 
relatively rapid process compared to polyplexes. Rejma et al. described that internalization 
process of latex beads with 50-100 nm diameter was faster than the process of 200 nm 
particles 48. 
 
CONCLUSION 
In summary, we have elaborated and characterized three different vectors for pDNA 
delivery to human neuronal precursor NT2 cells. Their transfection efficiency and cellular 
uptake were analyzed along the time observing a correlation between both processes. In 
order to further understand the behavior of the complexes inside the cells, we determined 
the uptake mechanism of lipoplexes and polyplexes, concluding that they enter the cells 
mainly via CME and CvME, respectively. Also, at four hours the complexes were localized 
in the late endosome and were able to release the DNA. Differences in the internalization 
velocity were observed between lipoplexes and polyplexes. The DNA carried by lipoplexes 
was localized in the nucleus at six hours while the DNA carried by polyplexes remained in 
the late endosome. It is hard to draw general conclusions about how to produce complexes 
with optimal transfection efficiencies. Therefore, it is essential to evaluate and design an 
appropriate vector for each cell line. According to our results, the cellular uptake of the 
complexes is a bottleneck in the transfection process of NT2 cells. Overall, this work gives 
some knowledge about the main aspects that need to be considered for the design and 
development of novel non-viral vectors to efficiently transfect human neuronal precursor 
NT2 cells as a first step in the development of a suitable platform for the delivery of 
exogenous biological agents into the CNS.  
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